Oric Pharmaceuticals, Inc. (ORIC): Total Liabilities
$24.53M
As of 2025-12-31
$23.43M
As of 2026-06-30
-0.4%
3-year compound annual growth
+21.6%
5-year compound annual growth
| Period ended | Total Liabilities | Change YoY | Source filing |
|---|---|---|---|
| 2025-12-31 | $24.53M | -20.9% | 2026-02-23, Balance as of period end |
| 2024-12-31 | $31.02M | +11.1% | 2026-02-23, Balance as of period end |
| 2023-12-31 | $27.92M | +12.5% | 2025-02-18, Balance as of period end |
| 2022-12-31 | $24.83M | -3.3% | 2024-03-11, Balance as of period end |
| 2021-12-31 | $25.67M | +178.3% | 2023-03-16, Balance as of period end |
| 2020-12-31 | $9.22M | +50.7% | 2022-03-21, Balance as of period end |
| 2019-12-31 | $6.12M | n/a | 2021-03-23, Balance as of period end |
Total Liabilities at similar companies
| Company | Year ended | Total Liabilities | Change YoY |
|---|---|---|---|
| Oric Pharmaceuticals, Inc. (ORIC) | 2025-12-31 | $24.53M | -20.9% |
| Alumis Inc. (ALMS) | 2025-12-31 | $110.64M | +36.8% |
| Nkarta, Inc. (NKTX) | 2025-12-31 | $91.88M | -1.4% |
| Stoke Therapeutics, Inc. (STOK) | 2025-12-31 | $65.98M | +55.1% |
| Harrow, Inc. (HROW) | 2025-12-31 | $347.39M | +8.7% |
| Tango Therapeutics, Inc. (TNGX) | 2025-12-31 | $52.51M | -55.1% |
| Erasca, Inc. (ERAS) | 2025-12-31 | $70.98M | -10.2% |
| MoonLake Immunotherapeutics (MLTX) | 2025-12-31 | $119.95M | +388.8% |
| Oncotelic Therapeutics, Inc. (OTLC) | 2025-12-31 | $131.36M | +584.2% |
Compare ORIC, ALMS, NKTX, STOK side by side · Screen every company in Pharmaceutical Preparations ↗